Redeye provides a research update following the Q3 report published by Alzinova earlier today. The report contained no major surprises, with financials in line with our expectations. Mainly, Alzinova achieved important regulatory milestones during the quarter as the company received FDA approval of its IND application for a phase II study and was granted a Fast Track Designation for ALZ-101.
